Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Table 4 Summary of studies with relatively large cohort of patients who underwent hepatectomy for liver metastasis from gastrointestinal stromal tumors

Ref.	Year	Period	No. of patients underwent hepatectomy	MST (mo)	3-ysr (%)	5-ysr (%)	3-yPFS (%)	No. of patients with TKI	Factors associated with worse overall survival
DeMatteo et al[26]	2001	1982-2000	341	391	501	301	451	NR	Interval from primary tumor diagnosis ≤ 24 mo2
Nunobe et al[27]	2005	1984-2003	18	36	64	34	NR	3 (17%)	NR
Xia et al[28]	2010	2005	19	33 (mean)	90	NR	NR	19 (100%)	Non-surgical therapy2
Turley et al[29]	2012	1995-2010	39	Not reached at 5 yr	68	NR	NR	27 (73%)3	Non-TKI therapy, extrahepatic disease
Bauer et al[30]	2014	Until 2011	104	96	NR	NR	NR	> 84%	Male4, R2 resection4, progression disease to TKI at the time of surgery4, extrahepatic disease4
Du et al[31]	2014	NR	19	Not reached	NR	NR	88 (2-yr)	19 (100%)	Non-surgical therapy2
Seesing et al[32]	2016	1999-2014	48	90	80	76	67	42 (88%)	Margin status (R1,2)

¹Including gastrointestinal sarcoma;

²Copmarison to the non-operation group;

³Excluding two patients lost to follow-up;

⁴Results including resections of extrahepatic metastasis. GIST: Gastrointestinal stromal tumor; MST: Median survival time; ysr: Year survival rate; PFS: Progression-free survival; TKI: Tyrosine kinase inhibitor; NR: Not reported.